Following a blood clot removal, John McCain was diagnosed with Glioblastoma, a cancer with even worse prognosis than pancreatic cancer. For decades, patients diagnosed with Glioblastoma multiforme (GBM) received an almost certain death sentence, with average survival times measured in months. Yet the approval of the most scifi-esque cancer therapy to date, Tumor-treating fields (Optune,… Continue reading John McCain, Glioblastoma & Novocure’s Electric Cancer-killing Machine
The next big cancer drug may already be stocked on our pharmacy shelves without us even know it, ready to take a punch out of some new disease! Here, we consider the robust potential of drug repurposing (AKA drug repositioning, re-profiling, re-tasking or therapeutic switching). Even prior to dawn of modern medicine, it was common… Continue reading Don’t call it a comeback – rethinking, drug repurposing
Biotech stocks have had a rough break since the Turing fiasco in late 2015. While this negative publicity reflects a moderate amount of risk to large pharmaceutical companies with broad drug portfolios, it has created myriad investment opportunities in early stage companies. Here we discuss Celldex Therapeutics (NASDAQ:CLDX), a stock whose current drug pipeline shows… Continue reading Biotech Beat: Celldex Therapeutics (CLDX)
While the age-old battle of the sexes will never be decisively won, there are certain arenas where the balance is strongly tipped. Cancer risk is one of these. Check out the list below to see where each sex stands in the fight against “the worst scourge of mankind.” 1. Women suffer from more sex-specific cancers.… Continue reading Which sex has it worse when it comes to cancer?